Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Treatment approach changed, and insufficient population

Conditions

Retinal Detachment
Rhegmatogenous Retinal Detachment

Interventions

DRUG: Lamivudine 300 MG
DRUG: Placebo

Sponsor

University of Wisconsin, Madison